E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

NCT ID: NCT01133977

Last Updated: 2016-10-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 97 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-04-30
• Study Completion Date: 2014-11-30

Brief Summary

Primary:

• Phase Ib: To define the safety, tolerability and maximum tolerated dose (MTD) of lenvatinib administered in combination with dacarbazine.
• Phase II: To evaluate the safety and tolerability of lenvatinib administered in combination with dacarbazine, compared with dacarbazine alone.

Secondary:

-Phase II: To make a preliminary assessment of the efficacy of lenvatinib administered in combination with dacarbazine, compared with dacarbazine alone.

Detailed Description

Safety was assessed by monitoring and recording all treatment emergent adverse events (AEs) and serious adverse events (SAEs); regular monitoring of clinical laboratory parameters; periodic measurement of vital signs and electrocardiograms (ECGs); dose limiting toxicities; performance of physical examinations; concomitant medications and procedures.

Conditions

Stage IV Melanoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Lenvatinib + Dacarbazine (Phase 1b)

Participants received 16 mg, 20 mg or 22 mg lenvatinib once daily in combination with dacarbazine

Group Type: EXPERIMENTAL

Lenvatinib

Intervention Type: DRUG

Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle

Dacarbazine

Intervention Type: DRUG

Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.

Lenvatinib + Dacarbazine (Phase 2)

Participants received lenvatinib per the maximum tolerated dose (MTD) as determined in the Phase Ib of the study in combination with dacarbazine

Group Type: EXPERIMENTAL

Lenvatinib

Intervention Type: DRUG

Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle

Dacarbazine

Intervention Type: DRUG

Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.

Dacarbazine (Phase 2)

Participants received dacarbazine

Group Type: ACTIVE_COMPARATOR

Dacarbazine

Intervention Type: DRUG

Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.

Interventions

Lenvatinib

Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle

Intervention Type: DRUG

Lenvatinib

Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle

Intervention Type: DRUG

Dacarbazine

Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.

Intervention Type: DRUG

Other Intervention Names

E7080; E7080; Dacarbazine (DTIC)-Dome

Eligibility Criteria

Inclusion Criteria

1. Patients with histologically-confirmed metastatic melanoma (Stage IV, American Joint Committee on Cancer (AJCC)).

2. No prior cytokine, chemotherapy, or targeted therapy for Stage IV melanoma.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

4. Life expectancy greater than or equal to 3 months.

5. At least 1 site of measurable disease by RECIST 1.1.

6. Adequate hematologic, renal, liver, and coagulation system function as defined by laboratory values performed within 21 days prior to initiation of dosing.

7. Blood pressure must be well-controlled (less than or equal to 140/90 mmHg at screening) with or without antihypertensive medication. Patients must have no history of hypertensive crisis or hypertensive encephalopathy.

Exclusion Criteria

1. Known central nervous system (CNS) lesions, except for asymptomatic, nonprogressive, treated brain metastases. Treatment for brain metastases must have been completed at least 4 weeks prior to Day 1 and may include whole brain radiotherapy (WBRT), radiosurgery [RS; Gamma Knife, linear accelerator (LINAC), or equivalent] or a combination as deemed appropriate by the treating physician. Dexamethasone must be discontinued at least 3 weeks prior to Day 1. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded.

2. Lactate dehydrogenase greater than or equal to 2.0 x upper limit of normal (ULN).

3. Subjects with proteinuria greater than 1+ on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Subjects with 24-hour urine protein greater than or equal to 1 g/24 hours will be ineligible.

4. Pregnant, breast-feeding, or refusing double barrier contraception, oral contraceptives or avoidance of pregnancy measures.

5. Other active malignancy.

6. History of or known carcinomatous meningitis.

7. History of or known ocular melanoma.

8. Are currently receiving any other treatment for the tumor (including palliative radiotherapy) aside from control of symptoms.

9. Received treatment in another clinical study within the 30 days prior to commencing study treatment or patients who have not recovered from side effects of an investigational drug to grade less than or equal to 1, except for alopecia.

10. Received radiotherapy within the 30 days prior to commencing study treatment or have not recovered from side effects of all radiation-related toxicities to grade less than or equal to 1, except for alopecia.

11. Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury within the 28 days prior to commencing study treatment. Minor surgery such as Portacath placement or skin biopsy is permitted if greater than or equal to 7 days have passed.

12. History of bleeding diathesis or coagulopathy.

13. Current use of anti-coagulants such as Vitamin K antagonists, unfractionated heparin, or low molecular weight heparin.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Quintiles, Inc.

INDUSTRY

Sponsor Role: collaborator

Eisai Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dave Harish

Role: STUDY_DIRECTOR

Quintiles, Inc.

Locations

Hagerstown, Maryland, United States

Albany, New York, United States

Greenville, South Carolina, United States

Dallas, Texas, United States

Norfolk, Virginia, United States

Berlin, , Germany

Berlin, , Germany

Berlin, , Germany

Heidelberg, , Germany

München, , Germany

Bari, , Italy

Milan, , Italy

Milian, , Italy

Napoli, , Italy

Siena, , Italy

Barcelona, , Spain

Madrid, , Spain

Madrid, , Spain

Madrid, , Spain

Valenica, , Spain

Dorset, , United Kingdom

Glasgow, , United Kingdom

Manchester, , United Kingdom

Metropolitan Borough of Wirral, , United Kingdom

Middlesex, , United Kingdom

Oxford, , United Kingdom

Southampton, , United Kingdom

Countries

United States; Germany; Italy; Spain; United Kingdom

Other Identifiers

E7080-702

Identifier Type: -

Identifier Source: org_study_id